Patent details

Basic Information

Publication number:

EP3835297

PCT Application Number:

Type:

European Patent Granted for LU

Legal Status:

Unitary Effect Registered

Application number:

EP202064234

PCT Publication Number:

First applicant's nationality:

Translation Language:

EPO Publication Language:

English

English Title of Invention:

SYNTHESIS AND INTERMEDIATES OF (R)-1(2,2 -DIFLUOROBENZO[D][1,3]DIOXOL-5YL)-N-(1-(2,3-DIHYDROXYPROPYL)-6-FLUORO-2-(1-HYDROXY-2-METHYLPROPAN-2YL)-1H-INDOL-5YL)CYCLOPROPANECARBOXAMIDE

French Title of Invention:

SYNTHÈSE ET INTERMÉDIAIRES DE (R)-1(2,2-DIFLUOROBENZO[D][1,3]DIOXOL-5-YL)-N-(1-(2,3-DIHYDROXYPROPYL)-6-FLUORO-2-(1-HYDROXY-2-MÉTHYLPROPANE-2YL)-1H-INDOL-5-YL) CYCLOPROPANECARBOXAMIDE

German Title of Invention:

SYNTHESE UND ZWISCHENPRODUKTE VON (R)-1-(2,2-DIFLUOROBENZO[D][1,3]DIOXOL-5-YL)-N-(1-(2,3-DIHYDROXYPROPYL)-6-FLUOR-2-(1-HYDROXY-2-METHYLPROPAN-2-YL)-1H-INDOL-5-YL)CYCLOPROPANECARBOXAMID

SPC Number:

Unitary Effect

Unitary Effect Requested:

Yes

Unitary Effect Request Filing Date:

07/06/2023

Link to UPP Register:

European Patent Register

Unitary Effect Request Withdrawal Date:

Unitary Effect Status:

Unitary Effect Registered

Unitary Effect Acceptance Decision Date:

12/06/2023

Unitary Effect Rejection Decision Date:

Unitary Effect Date:

07/06/2023

Unitary Effect Registration Date:

12/06/2023

Unitary Effect Re-establishment of rights Filing Date:

Unitary Effect Re-establishment of rights EPO Decision :

Unitary Effect Re-establishment of rights EPO Decision Date:

Explanatory Text UE:

Safety Net Request Date:

Safety Net Decision Date:

Safety Net Decision Outcome:

SPC Number:

Dates

Filing date:

25/03/2011

Grant date:

07/06/2023

EP Publication Date:

16/06/2021

PCT Publication Date:

Claims Translation Received Date:

Translations Received Date (B1 EP Publication):

Translations Received Date (B2 EP Publication):

Translations Received Date (B3 EP Publication):

Publication date:

07/06/2023

EP B1 Publication Date:

07/06/2023

EP B2 Publication Date:

EP B3 Publication Date:

Lapsed date:

Expiration date:

25/03/2031

Renunciation date:

Revocation date:

Annulment date:

Owner

From:

31/05/2023

 

 

Name:

Vertex Pharmaceuticals Incorporated

Address:

50 Northern Avenue, Boston, MA 02210, United States (US)

Inventor

1

Name:

LEE, Elaine Chungmin

Address:

United States (US)

2

Name:

ALCACIO, Tim Edward

Address:

United States (US)

3

Name:

KRAWIEC, Mariusz

Address:

United States (US)

4

Name:

KESHAVARZ-SHOKRI, Ali

Address:

United States (US)

5

Name:

ZHANG, Yuegang

Address:

United States (US)

6

Name:

ZHANG, Beili

Address:

United States (US)

Priority

1

Priority Number:

31737610 P

Priority Date:

25/03/2010

Priority Country:

United States (US)

2

Priority Number:

31995310 P

Priority Date:

01/04/2010

Priority Country:

United States (US)

3

Priority Number:

32156110 P

Priority Date:

07/04/2010

Priority Country:

United States (US)

4

Priority Number:

32163610 P

Priority Date:

07/04/2010

Priority Country:

United States (US)

Classification

IPC classification:

C07D 405/12;

Publication

European Patent Bulletin

1

Issue number:

202323

Publication date:

07/06/2023

Description:

Grant (B1)

2

Issue number:

202328

Publication date:

12/07/2023

Description:

Unitary Effect Request Receipt

3

Issue number:

202328

Publication date:

12/07/2023

Description:

Unitary Effect Request Acceptance

Annual Fees

Annual Fee Due Date:

Annual Fee Number:

Expected Payer:

Last Annual Fee Payment Date:

Last Annual Fee Paid Number:

Payer:

Filing date	Document type	Number of pages